Skip to main content

Advertisement

Table 5 EORTC QLQ-BR23 mean scores (SE) at each time point

From: Health-related quality of life in survivors of stage I-II breast cancer: randomized trial of post-operative conventional radiotherapy and hypofractionated tomotherapy

  CR & TT at T0 CR at T1 TT at T1 CR at T2 TT at T2 CR at T3 TT at T3 CR at T4 TT at T4 CR at T5 TT at T5
n=121 n=62 n=59 n=62 n=59 n=50 n=51 n=30 n=36 n=16 n=18
arm symptoms 24,33 21,00 (2,50) 18,07 (2,32) 21,24 (2,82) 18,01 (2,08) 22,02 (3,73) 26,33 (4,27) 19,89 (5,10) 19,96 (4,40) 11,14 (5,76) 18,78 (6,49)
breast symptoms 20,94 33,30 a (2,78) 29,57 (2,74) 23,67 (2,58) 24,10 (2,35) 17,99 (3,17) 15,94 (2,52) 14,55 (4,24) 12,60 (3,30) 6,87 (5,63) 16,77 (4,99)
body image 73,35 69,60 (2,14) 70,62 (2,49) 73,21 (2,48) 77,80 (2,55) 74,74 (3,67) 77,51 (2,87) 73,62 (5,76) 78,40 (4,93) 74,91 (7,02) 79,08 (7,36)
future perspective 53,44 57,33 (3,64) 51,02 (3,44) 58,36 (3,38) 58,62 (3,26) 61,78 (4,03) 65,44 (3,53) 64,55 (5,84) 64,55 (6,27) 59,69 (7,59) 68,03 (10,08)
systemic treatment side effects 14,64 22,50 (1,87) 25,81a (2,83) 22,52 (2,06) 21,21 (2,88) 18,01 (2,20) 17,88 (2,57) 19,40 (3,19) 13,20 (2,95) 17,62 (4,80) 15,24 (4,28)
  n=21 n=22 n=26 n=16 n=20 n=8 n=10 n=8 n=6 n=3 n=3
upset by hair loss 34,92 48,25 a (8,16) 27,51 (9,26) 23,81 a (11,11) 40,48 a (5,56) 46,02 a (11,10) 28,25 a (16,33) 1,62 a (0,00) 23,81 (29,40) 34,92 a (0,00) 34,92 a (0,00)
  n=104 n=53 n=50 n=53 n=53 n=42 n=45 n=26 n=30 n=13 n=15
sexual functioning 23,85 21,02 (2,68) 23,52 (3,45) 24,48 (3,04) 22,60 (3,36) 24,65 (3,50) 24,59 (2,90) 21,85 (4,44) 27,19 (3,61) 25,14 (6,92) 21,63 (5,36)
  n=61 n=23 n=23 n=29 n=32 n=24 n=29 n=15 n=19 n=8 n=9
sexual enjoyment 55,74 53,98 (5,39) 47,40 (3,31) 48,16 (5,77) 50,61 (5,45) 61,29 a (4,86) 49,94 (4,98) 64,07 (5,98) 48,59 (5,16) 62,40 a (6,67) 46,21 (9,52)
  1. a Indicates more or equal to ten-point difference from previous time point.
  2. T0: baseline, T1: last day RT, T2: 3 months post-RT, T3: 1 year post-RT, T4: 2 years post-RT, T5: 3 years post-RT.